Two murine models, C3H 38C13 B-cell lymphoma and AKR SL2 I cell lymphoma were used to determine the efficacy of three different Interferon preparations, recombinant human hybrid interferon-a A/D, recombinant murine Interferon (rMIFN)-7, and natural MIFN-a//3 (>85% ß), alone and in combination with tumor specific and nonspecific monoclonal antibody therapy. All three Interferon preparations hav...